RNA medicines and biotechnology innovation by Arcturus Therapeutics
Arcturus Therapeutics joins 39th National CF Education Conference to expand rare disease engagement
Arcturus Therapeutics will participate in the 39th National CF Education Conference, which begins tomorrow. The company invites attendees to visit their table and connect directly with their ...
Scientific presentations at Arcturus Therapeutics rare disease event welcome family participation
Arcturus Therapeutics has announced that families are invited to join its upcoming virtual presentations focused on scientific and clinical aspects of rare diseases, including urea cycle disorders ...
Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026
Arcturus Therapeutics presented a new research poster at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting. The company highlighted its ongoing efforts in developing ...
Arcturus Therapeutics urges new solutions as 10 percent of cystic fibrosis patients still lack effective treatment
Arcturus Therapeutics draws attention to a critical gap in cystic fibrosis care, noting that while innovative therapies have transformed treatment for about 90 percent of patients, approximately ...
Arcturus Therapeutics unveils OTC deficiency research at SIMD 2026 Annual Meeting
Arcturus Therapeutics is set to present its latest research on ornithine transcarbamylase (OTC) deficiency at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting. The company ...
Arcturus Therapeutics features Chief Medical Officer in The Bonnell Foundation podcast discussion
Arcturus Therapeutics took part in The Bonnell Foundation: Living with Cystic Fibrosis podcast, featuring Chief Medical Officer Alan H. Cohen, MD. The conversation focused on living with cystic ...
Arcturus Therapeutics stresses importance of phased clinical trials in drug development
Arcturus Therapeutics asserts that clinical trials play a pivotal role in turning scientific discovery into new treatments. The company emphasizes that each phase of clinical testing provides ...
Patients and scientists join forces for rare disease progress, Arcturus Therapeutics asserts
Arcturus Therapeutics convened key players from translational biology, clinical development, and the patient community for Rare Disease Day. The event aimed to create new momentum in ...
Arcturus Therapeutics to attend Leerink Partners 2026 Global Healthcare Conference
Arcturus Therapeutics announced it will attend the upcoming Leerink Partners 2026 Global Healthcare Conference. The company aims to present its advancements in mRNA therapeutics and rare disease ...
Arcturus Therapeutics reports financial results and pipeline progress
Arcturus Therapeutics has released its financial results for the fourth quarter and fiscal year, providing investors with updated figures and insight into its mRNA therapeutic programs. The ...
Arcturus Therapeutics warns of severe risks from OTC deficiency
Ornithine transcarbamylase (OTC) deficiency presents significant health risks when ammonia builds up in the body. Arcturus Therapeutics highlights the critical role OTC plays in the urea cycle and ...
